Xiomara Porras
Family · Oklahoma City, OKNPI 1245581883
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 491 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Johnson & Johnson at 31.0% of the total. 2025 is the largest year on record at $3,152, 2.3 times the $1,377 reported in 2021. Among family clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 491 payments — averaging $25.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$888
- plus $2K from 14 others
What the payments were for
- Food & beverage$12,05398%
- Education$2262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 157 | $3,801 |
| Otsuka America Pharmaceutical, Inc. | 68 | $1,693 |
| Alkermes, Inc. | 39 | $1,215 |
| AbbVie | 86 | $1,174 |
| Teva Pharmaceuticals USA, Inc. | 44 | $1,154 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $888 |
| Axsome Therapeutics, Inc. | 11 | $582 |
| Supernus Pharmaceuticals, Inc. | 5 | $324 |
| Neurocrine Biosciences, Inc. | 13 | $282 |
| Amgen | 5 | $271 |
| GSK | 6 | $204 |
| Lundbeck LLC | 6 | $139 |
| Vanda Pharmaceuticals Inc. | 5 | $134 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Indivior Inc. | 5 | $116 |
| Sunovion Pharmaceuticals Inc. | 5 | $95 |
| Idorsia Pharmaceuticals US Inc | 2 | $45 |
| Sage Therapeutics, LLC | 1 | $14 |
| Pfizer | 1 | $14 |
| Athena Bioscience, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,396
- SPRAVATO$721
- ARISTADA$469
- INVEGA SUSTENNA$403
- AUSTEDO$250
- REXULTI$246
- QELBREE$237
- ABILIFY ASIMTUFII$226
- ABILIFY MAINTENA$226
- Auvelity$225
- CAPLYTA$224
- Otezla$124
- Repatha$124
- COBENFY$122
- ARISTADA INITIO$117
- INVEGA TRINZA$116
- VRAYLAR$111
How this compares
$12,278 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 31 | $100,015 |
| IngrezzaValbenazine Tosylate | 11 | $92,904 |
| VraylarCariprazine Hcl | 60 | $90,347 |
| Abilify AsimtufiiAripiprazole | 13 | $59,661 |
| LybalviOlanzapine/Samidorphan Malate | 30 | $57,936 |
| AustedoDeutetrabenazine | 21 | $55,058 |
| RexultiBrexpiprazole | 14 | $27,803 |
| SpravatoEsketamine Hcl | 12 | $22,054 |
| Aripiprazole | 47 | $2,455 |
| Ziprasidone Hcl | 60 | $2,360 |
| Buspirone Hcl | 181 | $2,247 |
| Bupropion XlBupropion Hcl | 147 | $2,241 |
| Duloxetine Hcl | 131 | $2,109 |
| Quetiapine Fumarate | 152 | $2,099 |
| Olanzapine | 131 | $2,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Spravato | $3,801 | $122,06943 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $282 | $92,90411 claims |
| AbbVieVraylar | $1,174 | $90,34760 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti | $1,693 | $87,46427 claims |
| Alkermes, Inc.Lybalvi | $1,215 | $57,93630 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,154 | $55,05821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Anne DudeOklahoma City$11K
- Kailee AndersonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.